Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage.
about
Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegenerationThe role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesiumCerebrospinal fluid proteome profile in multiple sclerosis.The role of TPA I/D and PAI-1 4G/5G polymorphisms in multiple sclerosis.Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis.Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.Inhibition of myelin-cleaving poteolytic activities by interferon-beta in rat astrocyte cultures. Comparative analysis between gelatinases and calpain-IItPA receptors and the fibrinolytic response in multiple sclerosis lesions.A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitisAxonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple SclerosisA patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour.Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis.The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation.Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression.Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axisPhosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology.The plasminogen activator system: involvement in central nervous system inflammation and a potential site for therapeutic intervention.The abluminal endothelial membrane in neurovascular remodeling in health and disease.Fibrinogen depleting agent batroxobin has a beneficial effect on experimental autoimmune encephalomyelitis.Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling.Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the Proteinase Inhibitor 12 genePAI and TPA gene polymorphisms in multiple sclerosis.Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis.Myelin basic protein, an autoantigen in multiple sclerosis, is selectively processed by human trypsin 4.
P2860
Q21131975-16D26962-7E10-4552-9762-F90FA555F0CFQ26859190-9C3058D2-88C4-45D5-884E-76B6F9B13FBEQ33299647-85CF837E-8F81-449F-B376-6471D8E6591AQ33562755-B5F8381D-0252-4084-BDD0-AC6D01FD4E08Q33629803-C7ED8F84-695C-4304-BC67-B730B06C4A51Q33696788-FB65D369-D46B-4737-97FC-CD6B0EC37F48Q34374238-1A0D0CE0-1D98-4957-94B7-20FEFCB2A439Q34579845-0D86F11C-0D33-4B0B-9AE7-918BE1045BDFQ35083789-B1E617FC-5CC2-4328-8EDA-90CA9F81C478Q35085079-ACC30733-E738-4D4E-91B0-56B4671A1B3BQ35485799-AA49B506-E4A9-4453-B857-D05F976DA8A8Q35542637-3C56CEDE-6555-4E6E-AEF3-19CB6D376E01Q35587627-F991AA00-962D-4D03-9ACF-0237CEBC1C87Q35987823-8534C47F-7C5D-43E6-8078-11CF02B950C5Q36079853-4DB4BD44-3217-4A68-8573-D42289007832Q36445604-E3534B89-14D1-4DFE-AC85-51EEE824C045Q36605041-5BA937C5-0B29-4FD7-9D24-B4E3D5A19A28Q36962704-E5E0247C-659C-4F64-849F-486F9C88D9A5Q36973566-6C59168F-39EC-43B6-8145-A0E1FC5B68DAQ37366815-3BCE3E9D-709B-4075-AA75-ABB192248718Q38032676-ED5AF3D3-7C47-4A77-B07F-198DB183784AQ39619073-C0DC1184-7A2B-4C9E-838C-47F2B2D502FAQ40511087-2DB541F3-61F1-4F7F-A056-30E475DE3865Q42284657-69891C76-A5C9-4F5C-8FDF-81B36A87CC3AQ44812311-5E3D6953-A6DE-4A0E-B947-76B93602B455Q46149675-332E2194-1E18-4228-9E44-D80ED2ADAF34Q48427400-111B1724-463C-479C-AEAB-C3701343BE17Q53640728-F8C3BCD9-4A58-4BB8-961B-AAF4D6F5A8A4
P2860
Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Plasminogen activators in mult ...... ry response and axonal damage.
@en
Plasminogen activators in mult ...... ry response and axonal damage.
@nl
type
label
Plasminogen activators in mult ...... ry response and axonal damage.
@en
Plasminogen activators in mult ...... ry response and axonal damage.
@nl
prefLabel
Plasminogen activators in mult ...... ry response and axonal damage.
@en
Plasminogen activators in mult ...... ry response and axonal damage.
@nl
P2093
P356
P1433
P1476
Plasminogen activators in mult ...... ory response and axonal damage
@en
P2093
J Newcombe
M L Cuzner
N A van Lent
R Hanemaaijer
P304
P356
10.1093/BRAIN/124.10.1978
P407
P577
2001-10-01T00:00:00Z